Vaccination against meningococcal disease starts for teens aged 14 to 18 This spring, about 860,000 young people in the Netherlands will receive an invitation for a vaccination against meningococcal disease.
RIVM will make measurements around the Sint Maarten landfill From 21 January 2019, a team from RIVM will travel to Sint Maarten to make measurements and take samples at various locations around the landfill in Philipsburg.
Dutch air quality shows little improvement in 2017 In 2017, concentrations of nitrogen dioxide and particulate matter in most parts of the Netherlands were below European limit values.
Vaccination schedule for babies reviewed after introduction whooping cough vaccination for pregnant women Whooping cough is a dangerous disease for new born, unvaccinated babies. Starting at the end of 2019, the whooping cough vaccination will be offered nationwide to pregnant women.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
Rubber granulate on synthetic turf fields causes environmental impact Use of rubber granulate sourced from car tyres, on synthetic turf fields can be harmful to the environment in the close vicinity of these fields.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Climate change, ozone depletion and air quality need to be addressed coherently Ozone layer depletion, air pollution and climate change need to be addressed in connection with each other.
Meningococcal immunisation recommendations re-examined Meningococcal disease is a very serious infectious disease that can cause meningitis or blood poisoning. Children are immunised against meningococcal serogroup C at 14 months.